Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922342 | 0.95 | CHRNA7 (0.72) | CHRNA7MAPK1LMNATP53MAPT | |
| SCHEMBL16403251 | 0.94 | CHRNA7 (0.81) | CHRNA7MAPK1LMNATP53MAPT | |
| SCHEMBL5922348 | 0.91 | LMNA (0.69) | CHRNA7LMNATP53MAPTPOLB | |
| SCHEMBL7172634 | 0.89 | LMNA (0.67) | CHRNA7MAPK1LMNATP53MAPT | |
| SCHEMBL24157321 | 0.89 | CHRNA7 (0.59) | CHRNA7MAPK1LMNATP53MAPT | |
| SCHEMBL3027578 | 0.88 | CHRNA7 (0.77) | CHRNA7MAPK1LMNAALDH1A1 | |
| SCHEMBL2884407 | 0.88 | CHRNA7 (0.72) | CHRNA7LMNATP53MAPTPOLB | |
| SCHEMBL19808409 | 0.87 | CHRNA7 (0.74) | CHRNA7MAPK1TP53MAPT | |
| SCHEMBL13574377 | 0.86 | CHRNA7 (0.61) | CHRNA7MAPK1LMNATP53MAPT | |
| SCHEMBL3025992 | 0.85 | CHRNA7 (0.68) | CHRNA7MAPK1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316060-A1 | LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-09-26 | — | — | US | claimed |
| CN-117186241-A | Antibacterial peptide containing LL-37 sequence and application thereof | 国科温州研究院(温州生物材料与工程研究所) | 2023-12-08 | — | — | CN | claimed |
| US-20260124276-A1 | BIOENGINEERING TERITIARY LYMPHOID STRUCTURES USING CHITOSAN-BASED HYDROGELS | H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090438-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | DIRECT BIOLOGICS, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4728275-A1 | METHODS AND ASSAYS FOR IMMUNE PHENOTYPING | Immune Functional Diagnostics, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4545541-B1 | CIRCULARLY POLARIZED LIGHT-EMITTING MATERIAL AND USE, LIGHT-EMITTING DISPLAY DEVICE, AND DISPLAY APPARATUS | UNIV ZHEJIANG TECHNOLOGY (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034241-A1 | COMPOSITIONS AND METHODS FOR IN VIVO EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS | ONCOSENX INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260029409-A1 | MARKERS FOR DIAGNOSING INFECTIONS | MEMED DIAGNOSTICS LTD. (IL) | 2026-01-29 | — | — | US | disclosed |
| US-12485171-B2 | Methods of disease activity profiling for personalized therapy management | PROMETHEUS LABORATORIES INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250325599-A1 | A CLINICAL ISOLATED AVIRULENT STRAIN PROTECTS AGAINST WILDTYPE VIRULENT CLOSTRIDIOIDES DIFFICILE INFECTION | THE UNIVERSITY OF CHICAGO (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250305029-A1 | GENERATION OF PHASED READ-SETS FOR GENOME ASSEMBLY AND HAPLOTYPE PHASING | DOVETAIL GENOMICS, LLC | 2025-10-02 | — | — | US | disclosed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190106387-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR ANESTHESIA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-04-11 | — | — | US | disclosed |
| US-20180022698-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR ANESTHESIA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-01-25 | — | — | US | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022698-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR ANESTHESIA | GABRA5, GABRA4, GABRA6 | CHRNA7 38/4885MAPK1 4520/4885LMNA 3605/4885 |
| US-20260124276-A1 | BIOENGINEERING TERITIARY LYMPHOID STRUCTURES USING CHITOSAN-BASED HYDROGELS | CCL5, CCR9, CCL11 | CHRNA7 2362/4885MAPK1 2777/4885LMNA 4703/4885 |
| US-20260029409-A1 | MARKERS FOR DIAGNOSING INFECTIONS | AGER, TSG101, ST14 | CHRNA7 4733/4885MAPK1 2940/4885LMNA 4267/4885 |
| US-20260034241-A1 | COMPOSITIONS AND METHODS FOR IN VIVO EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS | CD47, CD74, ICOS | CHRNA7 2062/4885MAPK1 4427/4885LMNA 1160/4885 |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | CHRNA7 4787/4885MAPK1 3037/4885LMNA 4255/4885 |
| US-20190106387-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR ANESTHESIA | GABRA5, GABRA4, GABRA6 | CHRNA7 38/4885MAPK1 4520/4885LMNA 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.